The Clavicular Stack: Research Behind the Viral Protocol
Clavicular (Braden Peters) — Twitch streamer turned looksmaxxing icon — went viral for publicly documenting his GLP-1 agonist + BPC-157 peptide stack. Here is the complete research breakdown: mechanisms, clinical trial data, and how to replicate it with research-grade compounds.
-24.2%
Body weight (Phase 2 Agonist data, 48wks)
3
Compounds — Core Clavicular protocol
#1
Searched peptide stack 2025–2026
≥98%
Purity — research grade
Braden Peters — The Creator Who Made Peptides Mainstream
Clavicular is the online alias of Braden Peters — a Twitch streamer and content creator who became one of the most influential figures in the looksmaxxing community by doing something no mainstream creator had done before: publicly documenting his peptide stack in real time.
Unlike fitness influencers who vaguely allude to “TRT” or “PEDs,” Clavicular named compounds, discussed mechanisms, and tracked his body composition changes openly. His transparency created a feedback loop: viewers researched the compounds, corroborated the clinical data, and the looksmaxxing + peptide combination went mainstream.
His protocol centered on a GLP-1/GIP dual agonist (tirzepatide class) for body recomposition — the same compound class showing the most dramatic fat loss data ever recorded in clinical trials — paired with BPC-157 for recovery and gut protection during the GLP-1 protocol.
First mainstream creator to go public
Named GLP-1 agonist research peptides explicitly on stream — unprecedented for content creators at scale.
Made looksmaxxing + peptides mainstream
Search volume for 'clavicular peptide stack' and related terms exploded through 2025 and into 2026.
Protocol backed by clinical data
His core compound class (GLP-1/GIP dual agonists) is the most clinically validated weight loss mechanism outside bariatric surgery.
Inspired thousands to research GLP-1 agonists
His openness drove a wave of independent research into incretin agonism, dual receptor pharmacology, and BPC-157.
3 Compounds — The Core Clavicular Protocol
GLP-1/GIP Dual Agonist
Tirzepatide class — Body recomposition primary
-22.5%
Body weight, SURMOUNT-1 15mg
The anchor of the Clavicular stack. A dual agonist at the GLP-1 receptor (appetite suppression, glucose-dependent insulin secretion) and GIP receptor (adipose insulin sensitization, synergistic incretin signaling). This combination produces weight loss outcomes exceeding anything achievable through selective GLP-1 agonism alone.
-22.5%
Mean weight loss
SURMOUNT-1, 15mg, 72wk
57%
Lost ≥20% body weight
SURMOUNT-1 15mg arm
Dual
GIP + GLP-1 mechanism
Unique vs semaglutide class
47%
Greater loss vs sema
SURMOUNT-5 head-to-head
BPC-157
Body Protection Compound — Recovery & gut support
36+
Preclinical studies
BPC-157 (Body Protection Compound 157) is a pentadecapeptide derived from a partial sequence of human gastric juice protein. In Clavicular's protocol, it serves as the recovery and gut protection layer — particularly relevant during GLP-1 protocols, which can cause transient GI effects during dose escalation. Research interest centers on VEGFR2-mediated angiogenesis, gut mucosal integrity, and tendon/ligament healing.
VEGFR2
Primary angiogenic pathway
Gut
Mucosal protection mechanism
15AA
Pentadecapeptide length
The Protocol Approach
Weekly subcutaneous administration · 12–24 week research period · Dose escalation
Clavicular's protocol follows the standard SURMOUNT escalation model: start low to minimize GI effects during induction, titrate every 4 weeks, and hold at the maintenance dose through the research period. Subcutaneous administration, typically rotating injection sites (abdomen, thigh, upper arm).
Weekly
Administration frequency
12–24wk
Research period
SubQ
Route of administration
Why the Data Backs the Approach
Clavicular's protocol isn't anecdotal. The compound class he uses is the most clinically validated fat loss mechanism outside bariatric surgery.
| Trial | Compound / Dose | Duration | Weight Loss | Key Finding |
|---|---|---|---|---|
| SURMOUNT-1 | Tirzepatide 15mg | 72 weeks | -22.5% | 57% of participants lost ≥20% body weight |
| SURMOUNT-5 | Tirzep. vs Semaglutide | 72 weeks | 47% greater | -20.2% tirzep vs -13.7% sema head-to-head |
| SURMOUNT-1 (DXA) | Tirzepatide 15mg | 72 weeks | ~40% lean | ~40% of loss was lean mass (vs ~25% bariatric avg) |
| Phase 2 (Retatrutide) | Triple agonist 12mg | 48 weeks | -24.2% | Highest weight loss % recorded in a clinical trial |
Lean mass note: DXA data from SURMOUNT-1 showed approximately 40% of total weight lost was lean mass — a higher proportion than bariatric surgery (typically 20–25%). This is the research rationale behind stacking BPC-157 and resistance training with GLP-1 protocols to mitigate lean mass loss — exactly as Clavicular documented.
Replicating with Research-Grade Tirzepatide
The standard SURMOUNT dose escalation schedule — the same reference Clavicular's protocol follows.
| Weeks | Weekly Dose | Phase | Vial Needed |
|---|---|---|---|
| Weeks 1–4 | 2.5 mg | Initiation | 15mg (×6 doses) |
| Weeks 5–8 | 5 mg | Titration | 15mg (×3 doses) |
| Weeks 9–12 | 7.5 mg | Titration | 15mg (×2 doses) |
| Weeks 13–16 | 10 mg | Titration | 30mg covers 3 doses |
| Weeks 17–20 | 12.5 mg | Titration | 30mg covers 2–3 doses |
| Weeks 21+ | 15 mg | Maintenance | 15mg/vial = 1 dose |
Reconstitution with BAC Water
- 1Swab vial rubber stopper with alcohol. Allow to dry.
- 2Draw desired volume of bacteriostatic water into syringe.
- 3Inject BAC water slowly along the inner vial wall — not directly onto powder.
- 4Gently swirl until fully dissolved. Do not shake.
- 5Solution should be clear and colorless.
- 6Label with reconstitution date. Refrigerate.
15mg vial + 1.5mL BAC water = 10mg/mL solution. 15mg vial + 3mL BAC water = 5mg/mL solution.
Storage Requirements
Lyophilized (sealed vial)
-20°C
Up to 24 months
Avoid freeze-thaw cycles. Protect from light.
Reconstituted solution
2–8°C
Up to 28 days
BAC water extends stability vs sterile water.
GLP-2 T 15mg + Bacteriostatic Water
Everything needed to begin the Clavicular-inspired research protocol.
Frequently Asked Questions
What peptides does Clavicular take?
Clavicular (Braden Peters) has publicly documented a stack centered on a GLP-1/GIP dual agonist (tirzepatide class) for body recomposition, BPC-157 for recovery and gut protection, and has referenced additional compounds. His primary body recomposition compound is a GLP-1 receptor agonist — the same class as clinically approved tirzepatide.
Can you get Clavicular's exact peptides for research?
Research-grade tirzepatide (GLP-2 T) is available as a GLP-1/GIP dual agonist for laboratory research purposes. This is the same compound class Clavicular references as the core of his body recomposition protocol. BPC-157 is a separate compound and availability varies by vendor.
What are the results from Clavicular's protocol?
Clavicular documented significant body recomposition results publicly. The clinical data backing his primary compound is robust: tirzepatide 15mg shows -22.5% body weight loss at 72 weeks in SURMOUNT-1 (n=2,539), with 57% of participants achieving ≥20% body weight reduction. His results align with the Phase 2 retatrutide data showing up to -24.2% at 48 weeks.
What is the Clavicular stack?
Clavicular's core protocol centers on a GLP-1/GIP dual agonist (tirzepatide class) as the primary body recomposition compound, combined with BPC-157 for recovery support and gut protection during the GLP-1 protocol. The viral nature of his results stems from the clinical efficacy of dual incretin agonism — the most effective non-surgical weight loss mechanism identified in clinical trials to date.
Is tirzepatide the same as what Clavicular uses?
Tirzepatide (GLP-2 T) is the FDA-approved dual GLP-1/GIP receptor agonist — the same compound class Clavicular references as his primary body recomposition agent. Research-grade tirzepatide is used in laboratory settings studying incretin agonism, dual receptor pharmacology, and metabolic recomposition mechanisms.